1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Colorectal Cancer Diagnostics & Therapeutics Market - Segmented by diagnosis, technology and geography (2015 - 2020)

The global colorectal cancer diagnostics and therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 1-5% during the forecast period of 2015-2020. The market is valued at USD 14,143 million, as per 2015.

The CRC pipeline is highly robust, with a number of potential drug candidates present across the various phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or as second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. Along with these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.

The global colorectal cancer diagnostics and therapeutics market is segmented on the basis of:

Digital rectal examination
Fecal occult blood test
Flexible sigmoidoscopy
Surgery and radiation therapy
Targeted therapies
North America
Rest of the world
Some of the key players of the market are Abbott diagnostics, Alere, Beckman coulter, clinical genomics, Companion DX, EDP Biotech, Epigenomics AG, Exact sciences, Genomic tree, Metabiomics, Oncocyte, Quest Diagnostics, Randox Laboratories, Siemens Healthcare etc.


Increase of pipeline colorectal cancer screening tests
Aging population
Increasing consumer awareness


Cost of screening test

Table Of Contents

Global Colorectal Cancer Diagnostics and Therapeutics Market - Segmented by diagnosis, technology and geography (2015 - 2020)
1. Introduction

1.1 Report Description

1.2 Research Methodology

2 Executive summary

3. Market overview

3.1 Market definition

3.2 Market drivers

3.2.1 Increase of Pipeline Colorectal Cancer Screening Tests

3.2.2 Aging Population

3.2.3 Increasing Consumer Awareness

3.3 Market restraints

3.3.1 screening test costs

3.3.2 Counseling

3.4 Market opportunities

4. Portors five force analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Degree of comprtition

4.4 Threat of substitution

4.5 Threat of new entrants

5. Market segmentation

5.1 By diagnosis

5.1.2 Digital Rectal Examination

5.1.3 Fecal Occult Blood Test

5.1.4 Flexible Sigmoidoscopy

5.1.5 Colonoscopy

5.1.6 Virtual Colonoscopy

5.2 By treatment

5.2.1 Surgery and Radiation Therapy

5.2.2 Chemotherapy

5.2.3 Targeted Therapies

5.2.4 Resistance to Pharmacological Therapies

5.3 By geography

5.3.3 Middle East and Africa Qatar Saudi Arabia South Africa

6. Competitive Landscape

6.1 Mergers and Acquisitions

6.2 Agreements, Partnerships and Collaborations

6.3 New Product Launches

6.4 Recommendations to new market players

7. Company profiles

7.1 Abbott Diagnostics

7.2 Alere

7.3 Beckman Coulter

7.4 Clinical Genomics

7.5 Companion Dx

7.6 EDP Biotech

7.7 Epigenomics AG

7.8 Exact Sciences

7.9 Fujirebio (Miraca Holdings)

7.10 Genomic Tree

7.11 Metabiomics

7.12 Oncocyte (Biotime)

7.13 Quest Diagnostics

7.14 Randox Laboratories

7.15 Siemens Healthcare

7.16 Volition Rx

8 Appendix

8.1 Abbreviations

8.2 Sources

8.3 Bibliography

8.4 Disclaimer

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >

Infectious Disease Statistics and Therapy Market in the US

  • October 2016
    77 pages
  • Infectious Dise...  



  • United States  

View report >

Related Market Segments :

Colorectal Cancer


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.